RALYL Overexpression Suppresses Colorectal Cancer via Modulating HNRNPC ‐Mediated MNK2 Alternative Splicing
Cancer Reports · 2025
DOI: 10.1002/cnr2.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Zenghui Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Alternative Splicing, Protein Serine-Threonine Kinases, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inner Mongolia Science & Technology Plan, the Talent Training Program of Pudong Hospital affiliated to Fudan University (Project no. LJ202101), Fudan Zhangjiang Clinical Medicine Innovation Fund Projec….
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) stands as the second most prevalent cause of cancer‐related mortality globally, while its incidence holds the third position among newly diagnosed cancer cases worldwide. Colorectal carcinogenesis is complicated, and the processes are triggered by the complex interaction of some genetic and environmental factors, including DNA methylation. Previous studies showed that RALYL is hypermethylated in CRC. We aimed to explore the role of RALYL in CRC involved in MNK2 alternative splicing in the present study.
Methods
Bioinformatics analysis, detection in CRC samples, and experiments in vitro and in vivo combined with gene knockdown and overexpression were conducted. Cell proliferation and tumor growth assays were performed.
Results
Results showed that hypermethylated RALYL is lowly expressed in CRC. Overexpression of RALYL suppresses cell proliferation in vitro and tumor growth in vivo in CRC. MNK2 alternative splicing is essential for the tumor suppressive role of RALYL, along with RALYL regulating MNK2 alternative splicing via HNRNPC in CRC.
Conclusions
RALYL potentially exerts an inhibitory effect on CRC by engaging with HNRNPC to orchestrate the alternative splicing of MNK2. RALYL binds to HNRNPC to promote MNK2 splicing into MNK2a instead of MNK2b, consequently activating the p38 MAPK signaling pathway and inhibiting tumor proliferation in CRC. Our findings suggest that RALYL might suppress CRC through binding to HNRNPC to promote MNK2 splicing toward MNK2a, thereby activating the p38 MAPK signaling cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
- Department of Hepatobiliary Surgery, Pudong Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, The People's Hospital of Wuhai Inner Mongolia, Wuhai, Inner Mongolia, China.
ORCID-Profile: Feng Liu
Förderung
- Inner Mongolia Science & Technology Plan
- the Talent Training Program of Pudong Hospital affiliated to Fudan University (Project no. LJ202101), Fudan Zhangjiang Clinical Medicine Innovation Fund Projec…
Zitieren
APA
Ma, Z., Zhu, J., Chen, M., Wu, G., Liu, X., Hu, Z., Feng, Y., Wang, X., & Liu, F. (2025). RALYL Overexpression Suppresses Colorectal Cancer via Modulating HNRNPC ‐Mediated MNK2 Alternative Splicing. Cancer Reports. https://doi.org/10.1002/cnr2.70179
Vancouver
Ma Z, Zhu J, Chen M, Wu G, Liu X, Hu Z, et al. RALYL Overexpression Suppresses Colorectal Cancer via Modulating HNRNPC ‐Mediated MNK2 Alternative Splicing. Cancer Reports. 2025. doi:10.1002/cnr2.70179
BibTeX
@article{Ma2025,
author = {Ma, Zenghui and Zhu, Jianbin and Chen, Min and Wu, Guangming and Liu, Xiaolong and Hu, Zhanjun and Feng, Yufei and Wang, Xiaoliang and Liu, Feng},
title = {RALYL Overexpression Suppresses Colorectal Cancer via Modulating HNRNPC ‐Mediated MNK2 Alternative Splicing},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70179}
}
EUVIMED